Presentation of New Data on Inivata’s Industry-Leading Liquid Biopsy Platform at AACR 2018 Annual Meeting

11 April 2018

Oral presentations and posters to feature Inivata’s InVision® liquid biopsy platform and its application

Research Triangle Park, NC and Cambridge, UK, April 11, 2018 -- Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, announces that cutting-edge data on the performance of its liquid biopsy platform, InVision®, will be showcased in two oral presentations and two posters at the American Association for Cancer Research (AACR) Annual Meeting 14-18 April in Chicago. 

The details are as follows:

Presentation: Longitudinal circulating-tumor DNA profiling of EGFR-mutated non-small cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors

Date and time: April 15, 2018, 3:20PM - 3:35PM
Location: Room S105 - McCormick Place South (Level 1)

For the list of authors, click here. Webcast Available May 9

Presentation: Analytical validation of InVisionFirst™, a liquid biopsy assay for high-sensitivity broad molecular profiling of circulating tumor DNA using plasma samples of cancer patients
Date and time: April 15, 2018, 3:50PM - 4:05PM
Location: Room S105 - McCormick Place South (Level 1)

For the list of authors, click here. Webcast Available May 9


Poster: Integrative analysis of resistance to BRAF-targeted therapies in lung adenocarcinomas
Date and time: April 16, 2018, 8:00AM - 12:00PM
Location: Section 36

For the list of authors, click here.

Poster: Feasibility of an amplicon-based liquid biopsy for ALK and ROS1 fusions in advanced non-small cell lung cancer (NSCLC) patients
Date and time: April 17, 2018, 1:00 PM - 5:00 PM
Location: Section 27

For the list of authors, click here.

Media Contacts:
Consilium Strategic Communications
Chris Gardner/Laura Thornton
inivata@consilium-comms.com +44 (0)20 3709 5700


Karen Chandler-Smith
karen.chandler-smith@inivata.com +44 (0)7900 430235